Halozyme Therapeutics, Inc. (HALO) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | 180.08M | 219.03M | 178.6M | 99.71M | 154.22M | 178.47M | 115.38M | 55.79M | 129.43M | 102.35M | 132.41M | 66.84M |
| Operating CF Margin % | 47.8% | 48.48% | 50.41% | 30.61% | 58.23% | 59.89% | 39.77% | 24.12% | 66.07% | 44.49% | 61.29% | 30.24% |
| Operating CF Growth % | 16.77% | 22.73% | 54.8% | 78.71% | 19.16% | 74.36% | -12.87% | -16.53% | 48.83% | 24.14% | 90.15% | 66.17% |
| Net Income | 150.05M | -141.59M | 175.22M | 165.16M | 118.09M | 137.01M | 137.01M | 93.25M | 76.82M | 85.39M | 81.84M | 74.75M |
| Depreciation & Amortization | 33.73M | 26.68M | 22.28M | 22.35M | 20.45M | 22.26M | 20.36M | 22.17M | 22.04M | 22.52M | 22.4M | 22.45M |
| Stock-Based Compensation | 16.64M | 0 | 12.16M | 12.16M | 10.67M | 11.46M | 12.58M | 9.47M | 9.87M | 9.66M | 9.37M | 9.62M |
| Deferred Taxes | 3.43M | -16.77M | 0 | 0 | -2.86M | 0 | 292K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.43M | 360.14M | 20.05M | -37.64M | 390K | 32.55M | -926K | 14.48M | 17.82M | 1.4M | -5.23M | 31.39M |
| Working Capital Changes | -26.2M | -9.43M | -51.12M | -62.33M | 7.47M | -24.82M | -53.94M | -83.57M | 2.87M | -16.62M | 24.04M | -71.36M |
| Change in Receivables | -19.55M | -90.48M | -29.7M | -11.72M | 3.83M | -22.71M | -71.22M | -18.62M | 38.31M | -16.89M | 28.85M | -51.5M |
| Change in Inventory | 27.38M | 18.78M | -1.1M | -14.54M | -586K | -7.73M | 1.98M | -21.4M | -40.23M | 1.47M | 3.63M | -24.74M |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | -21.88M | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -2.88M | -741.79M | 201.61M | 84.79M | -90.42M | 29.48M | -167.48M | -42.04M | -82.68M | -8.29M | -83.45M | 54.99M |
| Capital Expenditures | -3.74M | -1.43M | -3.03M | -1.56M | -950K | -3.05M | -1.52M | -2.58M | -3.54M | -2.6M | -2.94M | 1.62M |
| CapEx % of Revenue | 0.99% | 0.32% | 0.86% | 0.48% | 0.36% | 1.02% | 0.52% | 1.12% | 1.81% | 1.13% | 1.36% | 0.73% |
| Acquisitions | 710K | -1.01B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 204.64M | 86.35M | 0 | 32.53M | 0 | -39.46M | -79.14M | -5.7M | -80.51M | 53.37M |
| Cash from Financing | -1.61M | 239.51M | -22.4M | -298.97M | -3.32M | -246.41M | 18.56M | 9.48M | -489K | -249.92M | 4.1M | 2.45M |
| Debt Issued (Net) | 0 | 235.37M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 4.15M | -38.88M | -300.17M | 0 | -250M | 18.56M | 0 | -489K | -252.3M | 0 | 1.05M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -38.88M | -300.17M | 0 | -250M | 0 | 0 | -489K | -252.3M | 0 | 1.05M |
| Other Financing | -1.61M | 0 | 16.48M | 1.2M | -3.32M | 3.58M | 0 | 9.48M | 0 | 2.38M | 4.1M | 1.4M |
| Net Change in Cash | 175.93M | -285.85M | 357.8M | -114.47M | 60.48M | -38.47M | -33.55M | 23.24M | 46.26M | -155.86M | 53.06M | 124.28M |
| Free Cash Flow | 176.34M | 217.6M | 175.57M | 98.15M | 153.27M | 175.41M | 113.86M | 53.21M | 125.88M | 99.76M | 129.47M | 68.47M |
| FCF Margin % | 46.81% | 48.17% | 49.56% | 30.13% | 57.87% | 58.86% | 39.25% | 23% | 64.27% | 43.37% | 59.93% | 30.97% |
| FCF Growth % | 15.05% | 24.05% | 54.2% | 84.45% | 21.76% | 75.84% | -12.06% | -22.28% | 66.54% | 24.53% | 88.65% | 74.4% |
| FCF per Share | 1.44 | 1.85 | 1.44 | 0.79 | 1.21 | 1.36 | 0.87 | 0.41 | 0.98 | 0.76 | 0.97 | 0.51 |
| FCF Conversion (FCF/Net Income) | 1.20x | -1.55x | 1.02x | 0.60x | 1.31x | 1.30x | 0.84x | 0.60x | 1.68x | 1.20x | 1.62x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 10.56M | 0 | 0 | 0 | 11.41M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |